Download Files:
ACT-389949
$199 – $2,750
Products Details
Product Description
– ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders[1][2].
Web ID
– HY-124071
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H18F2N6O3
References
– [1]Stalder AK,et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83(3):476-486.|[2]Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173.
CAS Number
– 1258417-54-7
Molecular Weight
– 428.39
Compound Purity
– 98.42
SMILES
– O=C(C1=C(C2=CC=CC(C)=C2)OC(C)=N1)NC3=NN(CC4=NC(C(F)(F)C)=CO4)N=C3
Clinical Information
– Phase 1
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 10 mg/mL (ultrasonic;adjust pH to 1 with HCl)
Target
– Formyl Peptide Receptor (FPR)
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
